The Limited Times

Now you can see non-English news...

US allocates $ 3.2 billion to research for antiviral drugs against Covid


US authorities on Thursday announced their intention to invest $ 3.2 billion to accelerate research and development of ...

American authorities announced Thursday their intention to invest $ 3.2 billion to accelerate research and development of antiviral drugs against Covid-19 and future pathologies.

Read also: United States: when discrimination in favor of minority restaurateurs is deemed discriminatory

This project, dubbed the “

antiviral program against pandemics

”, is financed with funds from the 1.9 trillion dollar stimulus plan, championed by Joe Biden and adopted by Congress in March. "

Antivirals are an important complement to existing vaccines, especially for individuals with certain diseases that may put them at greater risk, for those potentially less protected by vaccines,

" explained to journalists Dr Anthony Fauci, medical adviser of the White House.

These antiviral drugs could also play a role in the face of new variants against which vaccines currently in circulation offer less protection, he added.

The program will accelerate clinical trials for antiviral pills at different stages of their development, such as Molnupiravir from the Merck laboratory and drugs from Pfizer and Atea-Roche.

Read also: United States: surprise increase in jobless claims, again above 400,000

These antivirals should be taken by patients very soon after confirmation of infection to prevent the disease from reaching its most severe stage, such as oseltamivir for the flu. These 3.2 billion will also be used to finance the search for new antivirals, not only against SARS-CoV-2 or coronaviruses in general, but also against other families of viruses seen as presenting a potential pandemic threat.

Source: lefigaro

All business articles on 2021-06-21

You may like

News/Politics 2021-03-06T23:04:24.020Z
News/Politics 2021-04-12T18:55:52.917Z

Trends 24h

Business 2021-07-29T06:02:45.373Z


© Communities 2019 - Privacy